SLC6A3 and Parkinson disease: Indeed, the CSF lipidome signatures of Parkinson’s patients at early stages, de novo PD patients with abnormal dopamine transporters, and healthy controls show distinct lipidome changes, with a significant increase in glucosylceramide (GlcCer), while sphingomyelin (SM) was significantly reduced in GBA-PD patients [93].